bioAffinity Technologies Highlights CyPath Lung’s Role in Lung Cancer Risk Assessment at CHEST 2026

  • bioAffinity Technologies will present at CHEST 2026 on October 21, 2026, focusing on CyPath Lung’s use in lung cancer risk stratification.
  • CyPath Lung demonstrated 92% sensitivity, 87% specificity, and 99% negative predictive value in detecting lung cancer in high-risk patients with small nodules.
  • The company’s Medical and Scientific Advisory Board will discuss CyPath Lung’s expansion into the federal healthcare system and ongoing clinical studies.
  • bioAffinity is developing a new test for asthma and COPD-related lung inflammation, currently in investigational research.

bioAffinity Technologies is positioning CyPath Lung as a complementary tool to traditional imaging and clinical risk models, addressing the growing challenge of lung nodule management in high-risk patients. The company’s focus on noninvasive diagnostics aligns with broader industry trends toward early detection and precision medicine, particularly as lung cancer screening rates increase. The strategic involvement of its Medical and Scientific Advisory Board underscores the clinical relevance of its research and development efforts.

Clinical Adoption
How CyPath Lung’s binary result will integrate with existing imaging and clinical risk models to influence physician decision-making.
Regulatory Expansion
The pace at which CyPath Lung gains approval and adoption within the federal healthcare system.
R&D Progress
Whether bioAffinity’s investigational asthma and COPD test can translate into targeted therapies and precision medicine.